|Articles|February 25, 2007
Oriana Schwindt
Advertisement
Oriana Schwindt
Associate Editor
Oriana Schwindt worked as a reporter, writer, and researcher at several national publications (among them, BusinessWeek and Entertainment Weekly) before joining the Pharm Exec team as Associate Editor. She holds a BS in Journalism from the Medill School of Journalism at Northwestern University.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
Pharmaceutical Executive Daily: FDA Approves Datroway
5